NASDAQ:TNDMTandem Diabetes Care Stock Price, Forecast & News

Tandem Diabetes Care's stock was trading at $66.33 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TNDM shares have decreased by 7.5% and is now trading at $61.35. View which stocks have been mosted impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Tandem Diabetes Care.

Tandem Diabetes Care is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Tandem Diabetes Care.

Tandem Diabetes Care Inc (NASDAQ:TNDM) issued its quarterly earnings results on Monday, February, 24th. The medical device company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.03) by $0.07. The medical device company had revenue of $108.40 million for the quarter, compared to analyst estimates of $109.22 million. Tandem Diabetes Care had a negative net margin of 6.83% and a negative return on equity of 8.99%. The company's revenue was up 42.3% compared to the same quarter last year. During the same period last year, the company earned $0.02 EPS. View Tandem Diabetes Care's earnings history.

Tandem Diabetes Care's stock reverse split on the morning of Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.

Tandem Diabetes Care updated its FY 2020 After-Hours earnings guidance on Monday, February, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $450-465 million, compared to the consensus revenue estimate of $444.62 million.

13 brokers have issued 12-month price objectives for Tandem Diabetes Care's shares. Their forecasts range from $65.00 to $108.00. On average, they expect Tandem Diabetes Care's share price to reach $83.42 in the next year. This suggests a possible upside of 36.0% from the stock's current price. View analysts' price targets for Tandem Diabetes Care.

News articles about TNDM stock have been trending very negative on Saturday, InfoTrie reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Tandem Diabetes Care earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave media stories about the medical device company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutTandem Diabetes Care.

Tandem Diabetes Care saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 4,312,200 shares, an increase of 9.2% from the February 27th total of 3,950,000 shares. Based on an average trading volume of 1,210,300 shares, the short-interest ratio is presently 3.6 days. Currently, 7.6% of the shares of the company are sold short. View Tandem Diabetes Care's Current Options Chain.

Some companies that are related to Tandem Diabetes Care include Teleflex (TFX), Insulet (PODD), Hill-Rom (HRC), Novocure (NVCR), ABIOMED (ABMD), Penumbra (PEN), Haemonetics (HAE), ICU Medical (ICUI), Globus Medical (GMED), Integra Lifesciences (IART), Nevro (NVRO), NuVasive (NUVA), Irhythm Technologies (IRTC), Merit Medical Systems (MMSI) and AtriCure (ATRC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Ryder System (R), Pandora Media (P), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Tesla (TSLA) and Paypal (PYPL).

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TNDM stock can currently be purchased for approximately $61.35.

Tandem Diabetes Care has a market capitalization of $3.66 billion and generates $362.30 million in revenue each year. The medical device company earns $-24,750,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis. Tandem Diabetes Care employs 1,043 workers across the globe. View additional information about Tandem Diabetes Care.

The official website for Tandem Diabetes Care is http://www.tandemdiabetes.com/.

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at 858-366-6900 or via email at [email protected]